Диагностика и лечение бронхоэктазов. Рекомендации Испанского общества пульмонологов и торакальных хирургов (SEPAR)

1. Flume P.A., O'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957-969.

2. Máiz L., Baranda F., Coll R. et al. Normativa del diagnуsti co y el tratamiento de la afecciуn respiratoria en la fibrosis quнstica. Arch. Bronconeumol. 2001; 37: 316-324.

3. De Gracia J., Máiz L., Prados C. et al. Antibiуticos nebu lizados en pacientes con fibrosis quнstica. Med. Clin. (Barc.) 2001; 117: 233-237.

4. Cantón R., Cobos N., De Gracia J. et al. Antimicrobial ther apy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 2005; 11: 690-703.

5. Pasteur A.C., Helliwell S.M., Houghton S.J. et al. An investi gation into causative factors in patients with bronchiectasis.Am. J. Respir. Crit. Care Med. 2000; 162: 1277-1284.

6. Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12: 205-209.

7. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections. Eur.Respir.J. 2005; 6: 1138-1180.

8. Rosen M.J. Chronic cough due to bronchiectasis. ACCP Evidencebased clinical practice guidelines. Chest 2006; 129: 122S-131S.

9. Schünemann H.J., Jaeschke R., Cook D.J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommenda tions. Am. J. Respir. Crit. Care Med. 2006; 174: 605-614.

10. Kang E.Y., Miller R.R., Mьller N.L. Bronchiectasis: compar ison of preoperative thin section CT and pathologic findings in resected specimens. Radiology 1995; 195: 649-654.

11. de Gracia J., Rodrigo M.J., Morell F. et al. IgG subclass defi ciencies associated with bronchiectasis. Am. J. Respir. Crit. Care Med. 1996; 153: 650-655.

12. de Gracia J., Vendrell M., Бlvarez A. et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int. Immunopharmacol. 2004; 4: 745-753.

13. Rodrigo M.J., Vendrell M., Cruz M.J. et al. Utility of the antibody response to a conjugated Haemophilus influenzae type b vaccine for diagnosis of primary humoral immuno deficiency. Am. J. Respir. Crit. Care Med. 2000; 162: 1462-1465.

14. Vendrell M., de Gracia J., Rodrigo M.J. et al. Antibody pro duction deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005; 127: 197-204.

15. de Gracia J., Mata F., Бlvarez A. et al. Genotypephenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60: 558-563.

16. Noone P.G., Leigh M.W., Sannuti A. et al. Primary ciliary dyskinesia. Diagnostic and phenotypic features. Am. J. Respir. Crit. Care Med. 2004; 169: 459-467.

17. Stockley R.A., Bayley D., Hill S.L. et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001; 56: 366-372.

18. Angrill J., Agustн C., de Celis R. et al. Bronchial inflamma tion and colonization in patients with clinically stable bronchiectasis. Am. J. Respir. Crit. Care Med. 2001; 164: 1628-1632.

19. Wilson C.B., Jones P.W., O'Leary C.J. et al. Systemic mar ers of inflammation in stable bronchiectasis. Eur. Respir. J. 1998; 12: 820-824.

20. Ferrer A., Llorenз V., Codina G., de Gracia J. Nocardiosis y bronquiectasias. їUna asociación frecuente? Enferm. Infecc. Microbiol. Clin. 2005; 23: 62-66.

21. Maciá M.D., Blanquer D., Togores B. et al. Hypermutation is a key factor in development of multipleantimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 2005; 49: 3382-3386.

22. García+Castillo M., Morosini M.I., Valverde A. et al. Differences in biofilm development and antibiotic suscept bility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J. Antimicrob. Chemother. 2007; 59: 301-304.

23. Morosini M.I., García+Castillo M., Loza E. et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of hig range Etest strips. J. Clin. Microbiol. 2005; 43: 4480-4485.

24. Martínez+García M.A., Soler+Cataluсa J.J., Perpiсá+Tor+ dera M. et al. Factors associated with lung function decline in adult patients with stable noncystic fibrosis bronchiectasis. Chest 2007; 132: 1-8.

25. Shah P.L., Mawdsley S., Nash K. et al. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. Eur. Respir. J. 1999; 14: 1340-1344.

26. Griffith D.E., Aksamit T., Brown+Elliot B.A. et al. Diagnosis, treatment and prevention on nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175: 367-416. Диагностика и лечение бронхоэктазов. Рекомендации SEPAR

27. Davies G., Wells A.U., Doffman S. et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur. Respir. J. 2006; 28: 974-979.

28. Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.

29. Olveira G., Padilla A., Olveira C. Soporte nutricional en el paciente con patologнa pulmonar, enfermedad pulmonar obstructiva crуnica y fibrosis quнstica. In: Bellido D., De

30. Luis D., eds. Manual de metabolismo y nutriciуn. Madrid: Dнaz de Santos, SA; 2006. 455-470.

31. Martínez+García M.A., Perpiсá+Tordera M., Román+Sán+ chez P. et al. Qualityoflife determinants in patients with clinically stable bronchiectasis. Chest 2005; 128: 739-745.

32. Marco T., Asensio O., Bosque M. et al. Home intravenous antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 2000; 4: CD001917.

33. Smyth A.R., Tan K.H. Oncedaily versus multiple-daily dos ing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst. Rev. 2006; 3: CD002009.

34. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiecta sis. Chest 2006; 130: 1503-1510.

35. Wood D.M., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 2006; 1: CD004197.

36. Evans D.J., Bara A.I., Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst. Rev. 2007; 2: CD001392.

37. Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481-485.

38. Vendrell M., de Gracia J. Antibioticoterapia inhalada. Arch. Bronconeumol. 1997; 33: 41-48.

39. Saiman L., Marshall B.C., Mayer+Hamblett N. et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized con trolled trial. J.A.M.A. 2003; 290: 1749-1756.

40. Davis G., Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004; 59: 540-541.

41. Balfour+Lyn I.M., Lees B., Hall P. et al. Multicenter ran domized controlled trial of withdrawal of inhaled corticos teroids in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2006; 173: 1356-1362.

42. Martínez+García M.A., Perpiсá+Tordera M. et al. Inhaled steroids improve quality of life in patients with steadystate bronchiectasis. Respir. Med. 2006; 100: 1623-1632.

43. McCool F.D., Rosen M.J. Nonpharmacologic airway clear ance therapies: ACCP evidencebased clinical practice guidelines. Chest 2006; 129 (1 Suppl.): 250S-259S.

44. Bradley J.M., Moran F.M., Elborn J.S. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir. Med. 2006; 100: 191-201.

45. Crockett A.J., Cranston J.M., Latimer K.M., Alpers J.H. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2001; 1: CD001289.

46. Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2006; 2: CD002996.

47. O'Donnell A., Barker A.F., Ilowite J.S., Fick R.B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. hDNase study group. Chest 1998; 113: 1329-1334.

48. Roig J., Llorente J.L., Ortega F.J., Orriols R. Manejo de la hemoptisis amenazante. Available from: www.separ.es/publi+ caciones/normativas_y_procedimientos.html

49. Orens J.B., Estenne M., Arcasoy S. et al. International guide lines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2006; 25: 745-755.

50. Balkanli K., Genç O., Dakak M. et al. Surgical management of bronchiectasis: analysis and shortterm results in 238 patients. Eur. J. Cardiothorac Surg. 2003; 24: 699-702.

51. Lavery K., O'Neill B., Elborn J.S. et al. Selfmanagement in bronchiectasis: the patients' perspective. Eur. Respir. J. 2007; 29: 541-547.

52. Eastham K.M., Fall A.J., Mitchell L., Spencer D.A. The need to redefine noncystic fibrosis bronchiectasis in childhood. Thorax 2004; 59: 324-327.